<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514277</url>
  </required_header>
  <id_info>
    <org_study_id>VirtuaHealthExparel</org_study_id>
    <nct_id>NCT03514277</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Compare Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Pain Relief</brief_title>
  <official_title>Combined Administration of Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Analgesia in Posterior Lumbar Spine Surgery - A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virtua Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virtua Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information about how patients feel when doctors
      manage their pain after lumbar spine surgery using a combination of EXPAREL® and bupivacaine
      injected into the lumbar spine at the end of surgery, compared to the patients that doctors
      use only EXPAREL® or bupivacaine to manage their pain. This information will help doctors
      determine which approach works best for patients who will receive surgery in their lumbar
      spine in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean postoperative pain score</measure>
    <time_frame>Average of 3 days in hospital</time_frame>
    <description>Wong-Baker pain faces scale of 0-no pain, to 10-extreme pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of opioids during hospital stay</measure>
    <time_frame>Average of 3 days in hospital</time_frame>
    <description>All opioid analgesics will be converted into oral mg morphine equivalent to determine the total dose of opioids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to achieve physical therapy discharge criteria</measure>
    <time_frame>Average of 3 days in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of opioid related adverse events</measure>
    <time_frame>Average of 3 days in hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Lumbosacral Radiculopathy</condition>
  <condition>Lumbar Disc Degeneration</condition>
  <condition>Lumbar Disc Herniation</condition>
  <condition>Stenosis</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Spondylolysis</condition>
  <condition>Deformity of Spine</condition>
  <arm_group>
    <arm_group_label>Local infiltration of EXPAREL and Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Local infiltration of Exparel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Local infiltration of Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
    <arm_group_label>Local infiltration of EXPAREL and Bupivacaine</arm_group_label>
    <arm_group_label>Local infiltration of Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>30 mL bupivacaine 0.5% w/v solution</description>
    <arm_group_label>Local infiltration of EXPAREL and Bupivacaine</arm_group_label>
    <arm_group_label>Local infiltration of Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older;

          2. Primary indication is low back pain, lumbosacral radiculopathy, lumbar disc
             degeneration, lumbar disc herniation, stenosis, spondylolisthesis, spondylolysis, or
             deformity requiring surgical intervention;

          3. Scheduled to undergo primary, 1 or 2 level, posterior lumbar laminectomy with or
             without fusion, discectomy with fusion, or fusion at Virtua Memorial Hospital;

          4. Willing to provide informed consent, participate in study, and comply with study
             protocol.

        Exclusion Criteria:

          1. Hypersensitivity or allergy to local anesthetics;

          2. Pregnant or contemplating pregnancy prior to surgery;

          3. Previous surgery in lumbar spine (i.e. other than microdiscectomy);

          4. Prior treatment for alcohol, recreational drug, or opioid abuse;

          5. Serious spinal conditions (e.g. spinal cord compression, cauda equina syndrome, spinal
             infection, spinal tumor, spinal fracture, inflammatory or systemic spinal arthritis);

          6. Surgery involving more than 2 vertebral levels;

          7. Worker's compensation or personal injury related to lumbar spine (treatment outcomes
             may be affected by patient's personal interests [21]; could also run into potential
             issues with reimbursement).

          8. Lactating women

          9. Patients with end stage liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mojisola Otegbeye, PhD</last_name>
    <phone>(856)761-3905</phone>
    <email>motegbeye@virtua.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virtua Memorial Hospital</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Greenleaf, MD</last_name>
      <phone>609-267-9400</phone>
      <email>bob.greenleaf1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert Greenleaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Publish research findings in relevant peer-reviewed journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

